Bristol-Myers Squibb's Opdivo Fails to Show Superiority to Bayer's Nexavar in Liver Cancer 0 24.06.2019 03:00 Feedity.com The drug failed to meet statistical significance for overall survival. However, the company is putting a positive spin on it, saying it showed a clear improvement trend in OS for patients treated with Opdivo compared to sorafenib. Moscow.media Частные объявления сегодня Rss.plus Все новости за 24 часа
